RUXOLITINIB
ruxolitinib 10 mg tablet, 56
RUXOLITINIB (13245D)
13245D
Manner of administration:Oral
Restriction (Streamlined authority code: 13892)
Indication: Grade II to IV acute graft versus host disease (aGVHD)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 5 | DPMQ: $4,512.50 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Jakavi | |||||